MSInsight

Specialises in genomics and bioinformatics, is developing innovative diagnostic solutions for the analysis of microsatellite instability (MSI), a key biomarker in oncology. Using tools based on high-throughput sequencing (NGS) data, the company provides valuable information on microsatellite variations, optimising diagnosis and therapeutic guidance, particularly for immune checkpoint inhibitors. Its flagship product, MSIcare, aims to become a benchmark in diagnosis, prognosis and theranostics.